Pulmonary Embolism Clinical Trial
Official title:
Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using a Single Dose of Gadofosveset (Ablavar)
The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI).
Specific Aim 1: To assess first-pass SNR and CNR of pulmonary MR angiography performed with
0.03 mmol/Kg of intravenous gadofosveset trisodium.
Hypothesis: Use of 0.03 mmol/Kg of gadofosveset trisodium in gradient recalled echo pulmonary
MR angiography will provide a pulmonary artery SNR and CNR equal to or better than the SNR
and CNR obtained using the same MR technique with 0.2 mmol/Kg of a conventional contrast
agent (gadopentetate dimeglumine) and equal to or better than 0.1 mmol/Kg of intravenous
gadobenate dimeglumine. Data will be compared to SNR and CNR of pulmonary MR angiogram images
obtained at Washington University as part of the PIOPED III study.
Specific Aim 2: To assess SNR and CNR of breath-hold pulmonary MR imaging obtained
immediately after the original first-pass breath-hold pulmonary MR angiography.
Hypothesis: SNR and CNR of pulmonary MR angiography performed immediately after first-pass
breath-hold pulmonary MR angiography will be at least equal to the SNR and CNR obtained using
the same MR technique with 0.2 mmol/Kg of a conventional contrast agent (gadopentetate
dimeglumine) and at least equal to 0.1 mmol/Kg of intravenous gadobenate dimeglumine.
Specific Aim 3: To assess SNR and CNR of lower extremity MR venogram (MRV) performed
immediately after the two pulmonary MR angiograms, described above.
Hypothesis: SNR and CNR of passive lower extremity MRV performed after pulmonary MR
angiography will be equal to or better than the SNR and CNR obtained using the same passive
MRV technique with 0.2 mmol/Kg of a conventional contrast agent or 0.1 mmol/Kg of gadobenate
dimeglumine. Again, data will be compared to SNR and CNR of lower extremity
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00816920 -
Natural History of Isolated Deep Vein Thrombosis of the Calf
|